PMID- 35890100
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 15
IP  - 7
DP  - 2022 Jun 27
TI  - Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix 
      Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable 
      Atherosclerotic Plaque.
LID - 10.3390/ph15070802 [doi]
LID - 802
AB  - Atherosclerosis is a disorder in which, in addition to high cholesterol levels, 
      several plasma factors play a significant role in its development. Among these 
      cytokines and molecules are interleukin 6 (IL-6), interleukin 18 (IL-18), tumor 
      necrosis factor alpha (TNF-alpha), metalloproteinase 2 (MMP-2), and metalloproteinase 9 
      (MMP-9), all of which may contribute to the stabilization of atherosclerotic 
      plaque. The purpose of this study was to determine the effect of advanced 
      lipid-lowering therapy on the levels of these determinants by utilizing 
      proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors in patients 
      with verified high-risk atherosclerotic plaque. Methods: The study involved 
      patients with dyslipidemia who had the presence of unstable atherosclerotic 
      plaque verified by ultrasonography and who were eligible to begin alirocumab 
      treatment. The levels of IL-6, IL, 18, TNF-alpha, and MMPs were determined in this 
      group before and after three months of therapy. After treatment, a statistically 
      significant decrease in concentrations of Il-18, Il-6, TNF-alpha (p < 0.001) and 
      MMP-2 (p < 0.05) was observed. Additionally, we observed that the concentrations 
      of these markers were significantly higher in the group of patients prior to 
      initiating therapy than in the control group. Our study's results suggest that 
      PCSK-9 inhibitor therapy significantly reduces the concentration of factors 
      influencing the stability of atherosclerotic plaque, which may explain their 
      essential importance in reducing cardiovascular risk in patients receiving this 
      treatment.
FAU - Basiak, Marcin
AU  - Basiak M
AUID- ORCID: 0000-0003-0674-5612
AD  - Department of Internal Medicine and Clinical Pharmacology, Medical University of 
      Silesia, Medykow 18, 40-752 Katowice, Poland.
FAU - Kosowski, Michal
AU  - Kosowski M
AUID- ORCID: 0000-0003-2597-463X
AD  - Department of Internal Medicine and Clinical Pharmacology, Medical University of 
      Silesia, Medykow 18, 40-752 Katowice, Poland.
FAU - Hachula, Marcin
AU  - Hachula M
AUID- ORCID: 0000-0001-9023-676X
AD  - Department of Internal Medicine and Clinical Pharmacology, Medical University of 
      Silesia, Medykow 18, 40-752 Katowice, Poland.
FAU - Okopien, Boguslaw
AU  - Okopien B
AUID- ORCID: 0000-0001-7228-2906
AD  - Department of Internal Medicine and Clinical Pharmacology, Medical University of 
      Silesia, Medykow 18, 40-752 Katowice, Poland.
LA  - eng
GR  - PCN-1-185/N/9/O/Medical University of Silesia/
PT  - Journal Article
DEP - 20220627
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC9324132
OTO - NOTNLM
OT  - PCSK-9 inhibitors
OT  - atherosclerotic plaque
OT  - hyperlipidemia
OT  - interleukin-18
OT  - interleukin-6
OT  - metalloproteinase 2
OT  - tumor necrosis factor alfa
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/28 06:00
MHDA- 2022/07/28 06:01
PMCR- 2022/06/27
CRDT- 2022/07/27 01:38
PHST- 2022/05/07 00:00 [received]
PHST- 2022/06/22 00:00 [revised]
PHST- 2022/06/23 00:00 [accepted]
PHST- 2022/07/27 01:38 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/28 06:01 [medline]
PHST- 2022/06/27 00:00 [pmc-release]
AID - ph15070802 [pii]
AID - pharmaceuticals-15-00802 [pii]
AID - 10.3390/ph15070802 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2022 Jun 27;15(7):802. doi: 10.3390/ph15070802.